MSC Extracellular Vesicle Delivery Enhanced by pFUS Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mesenchymal stromal cell (MSC) therapies for tissue repair face challenges due to pulmonary trapping and inefficient delivery, limiting the therapeutic potential of extracellular vesicles (EVs) derived from MSCs, which are crucial for regenerative applications.
Innovation Solution
The use of pulsed focused ultrasound (pFUS) stimulation enhances the production and bioenergetic profile of MSC-derived EVs, increasing the levels of mitochondrial-related products such as miRNA, mRNA, and proteins, allowing for targeted delivery and improved therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If MSCs are injected intravenously for tissue repair, then they can reach distant target organs, but they are predominantly trapped in the lung microvasculature due to the pulmonary first pass effect
Solution Approach 1:
The patent extracts the therapeutic cargo (extracellular vesicles containing mitochondria-related products) from the whole MSCs. This allows the therapeutic agents to be delivered without the harmful pulmonary trapping effect that occurs with whole cell injection, while still achieving the desired tissue repair effect through the isolated EVs
Solution Approach 2:
The patent segments the MSC into smaller extracellular vesicles that can bypass the pulmonary first pass effect. The EVs are small enough to avoid lung microvasculature trapping while maintaining the ability to deliver therapeutic cargo to target tissues
2Device complexity
If conventional MSC therapy is used without enhancement, then the treatment approach is simple, but the therapeutic effect is limited due to cellular-energy deficiency and mitochondrial dysfunction
Solution Approach 1:
The patent applies preliminary action by pre-stimulating MSCs with pFUS before EV isolation to enhance the bioenergetic profile and mitochondrial content of the EVs. This preliminary enhancement ensures that the EVs contain sufficient mitochondria-related products to effectively treat diseases associated with cellular-energy deficiency
Solution Approach 2:
The patent changes the physical parameters of MSCs by applying pulsed focused ultrasound stimulation, which alters the bioenergetic state and mitochondrial function of the cells. This parameter change results in EVs with enhanced cargo containing mitochondria-related products that can restore bioenergetic health in diseased tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
pFUS-stimulated MSC-derived EVs effectively reduce inflammation, restore bioenergetic health, and promote tissue regeneration by delivering a cargo that includes mitochondria-related products, addressing cellular-energy deficiency and mitochondrial dysfunction.
Implementation Method 1
The use of pulsed focused ultrasound (pFUS) stimulation at low acoustic doses enhances the production and bioenergetic profile of the EVs from MSCs
Data Source
AI summary
Methods for treating diseases associated with inflammation driven cellular-energy deficiency or mitochondrial dysfunction are provided. The methods utilize extracellular vesicles derived from mesenchymal stromal cells (MSCs) that have been stimulated with sound waves. The use of pFUS stimulation at low acoustic doses enhances the production and bioenergetic profile of extracellular vesicles from MSCs. The extracellular vesicles derived from MSCs that have been stimulated with sound waves can be used to reduce inflammation, restore the bioenergetic health of injured cells, and promote regeneration of injured tissue through the release of the extracellular vesicle cargo, which contains mitochondria-related products.